Dihydrotestosterone (DHT) w/ Dihydroboldenone (DHB) & Sodium Valproate

A small glass vial labeled 'DHT' with a metal cap, filled with a clear liquid, against a black background.

Dihydroboldenone (DHB) is a synthetic anabolic-androgenic steroid structurally related to boldenone, discussed primarily in bodybuilding contexts for its strong androgenic and anabolic effects. It is not approved for medical use in most countries and is associated with risks typical of anabolic steroids, including hormonal suppression and cardiovascular concerns.

Sodium valproate is a prescription medication used clinically to treat epilepsy, bipolar disorder, and migraine prevention. It works by stabilizing neural activity through effects on GABA signaling and other cellular pathways. It is an HDAC inhibitor. Outside of approved indications, any experimentation carries significant risks and requires medical supervision due to potential liver, metabolic, and neurological side effects.

Dihydrotestosterone (DHT) is a potent active androgen (male sex hormone) synthesizes from testosterone by the enzyme 5-alpha reductase. While best known for regulating male reproductive and secondary sex characteristics, it also plays a key role in the brain. DHT is metabolized in the brain into a neurosteroid called (3-alpha-androstanediol). This metabolite acts as a potent positive allosteric modulator of the GABA-A receptor.

  • This page summarizes anecdotal reports and community observations, not medical evidence. Reports may be incomplete, biased or inaccurate and are not medical advice or recommendations. “Risk” here refers to how frequently severe or prolonged symptom worsening is reported, not to proven causation or population-wide probability. Individual responses vary widely, and absence of issues in some users does not rule out significant reactions in others.

  • PFS PSSD PAS Community Context & Proposed Mechanism: Within PFS/PSSD/PAS communities, the DHB + DHT & sodium valproate combination is discussed in relation to its potential interactions with androgen receptor signaling, epigenetic regulation, and GABAergic pathways. The theoretical rationale described by users combines three proposed targets: (1) strong androgen receptor activation (DHB), (2) epigenetic modulation via HDAC inhibition (valproate), and (3) GABAergic system effects (valproate & DHT which metabolizes into 3-a-diol which is a positive allosteric modulator of the GABA A recepotor), which some hypothesize could intersect with pathways implicated in persistent post-drug syndromes. Some write-ups frame this as an attempt to "force a reset" of dysregulated androgen signaling and downstream gene expression. It's important to emphasize that this rationale is theoretical, extrapolated from known pharmacology rather than validated in controlled studies for PFS/PSSD/PAS. These mechanisms may interact with pathways involving androgen receptor signaling, HDAC inhibition/epigenetic regulation, or GABAergic modulation that are often discussed in relation to PFS / PSSD / PAS. The success of these protocols may depend on an individuals genetics and whether they have the enzymes available to metabolize certain hormones For instance DHT: Primary clearance is driven by UGT2B15; secondary support is provided by UGT2B7. 3α-diol: Cleared jointly by both UGT2B15 and UGT2B17, which convert it into its glucuronide form for excretion.

  • Full Cure Anecdote. Highly Experimental w/ High Risks & Complexity. Only Tried 1 time:

    In community experimentation, there is one anecdote of an individual that ran 1g DHB, 1g DHT weekly with 2-3g sodium valproate daily for 3 months, who then took two months off taking nothing, and then when starting with very low dose testosterone, this individual became cured where oily skin returned, muscle pumps, libido, alcohol GABA response, etc.

    This is a highly experimental and risky approach that using illegal drugs and safety would need to be monitored by a trusted doctor.

    Evidence basis: 1 anecdote in WhatsApp groups, Established endocrinology of DHT, and steroid signaling; theoretical discussion around neurosteroid metabolites (e.g., 3α-diol) and GABA-A–related tone; anecdotal reports (online forums/self-reports). No controlled studies establishing safety or efficacy for PFS/PSSD/PAS.

  • One Cure in WhatsApp Group.

Public comments reflect individual experiences and opinions. They are not medical advice and may not be accurate or representative.

Return To Home